학술논문
674 A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients
Document Type
article
Author
Faye Johnson; Nashat Gabrail; Ammar Sukari; Barbara Burtness; Christine H Chung; Sara Pai; Lara A Dunn; Cristina Rodriguez; Marya Chaney; Apollina Goel; Ricklie Julian; Francis Worden; Rami Haddad; Douglas Adkins; A Dimitrios Colevas; Laura Agensky; Matteo Levisetti; Steven Margossian; Steve Quayle; Jong Chul Park; Robert M Jotte; Tanguy Y Seiwert; Nabil F Saba; Julie E Bauman; Michael K Gibson
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Language
English
ISSN
2051-1426